IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Analyst Tom Mackinnon of BMO Capital maintained a Hold rating on IGM Financial (IGIFF – Research Report), retaining the price target of ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...

IGM Biosciences (NASDAQ:IGMS) lost nearly two-thirds of its value on Friday after the company abandoned two antibody-based ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

IGM Biosciences (NASDAQ:IGMS) announced that it is currently evaluating internal options as well as potential strategic alternatives. Under these changes, it will halt further development of imvotamab ...

Check the time stamp on this data. Updated AI-Generated Signals for Ishares Expanded Tech Sector Etf (IGM) available here: IGM.

Shares of IGM Biosciences stock opened at $10.31 on Friday. The firm has a market cap of $613.03 million, a price-to-earnings ratio of -2.83 and a beta of 0.08. The business has a 50-day moving ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...